INDICATION OF THE PARENT PROTOCOL

Clinical trials for INDICATION OF THE PARENT PROTOCOL explained in plain language.

Never miss a new study

Get alerted when new INDICATION OF THE PARENT PROTOCOL trials appear

Sign up with your email to follow new studies for INDICATION OF THE PARENT PROTOCOL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Patients get extended access to experimental drug in safety Follow-Up

Disease control Not yet recruiting

This study allows participants who benefited from remibrutinib in previous Novartis trials to continue taking the medication for up to three years. It aims to collect long-term safety data on the drug. The study is open to people with skin or allergy conditions who cannot access …

Matched conditions: INDICATION OF THE PARENT PROTOCOL

Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Apr 01, 2026 14:41 UTC

INDICATION OF THE PARENT PROTOCOL

Get alerted when new INDICATION OF THE PARENT PROTOCOL trials appear

Patients get extended access to experimental drug in safety Follow-Up